retatrutide clinical trial weight loss for loss: Study shows 30% body weight New GLP-1 obesity drug, retatrutide,

Pathway paradigms revealed from the genetics of inflammatory bowel disease

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

In terms of tolerability, GLP-1RAs are commonly associated with GI side effects, which are often dose-dependent and time-limiting [55]

Four hours later, one familiar object that the mice explored less previously was switched to a novel object to avoid the spatial preference

Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects

Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes